Malpani Ventures

Dr. Aniruddha Malpani makes all investment decisions personally. He is an IVF specialist who built the Malpani Infertility Clinic in Mumbai, and he has been actively angel investing since roughly 2012. There is no separate investment committee or external manager.

The primary wealth originates from Dr. Malpani's medical practice — the Malpani Infertility Clinic, one of Mumbai's recognized IVF centers. This makes the firm structurally distinct from most Indian family offices, which typically derive capital from industrial, real estate, or pharmaceutical fortunes.

Deal flow arrives through multiple channels. Dr. Malpani's role as a limited partner in venture funds such as India Quotient and First Cheque provides institutional-grade referrals. He also co-invests alongside active angel networks like Indian Angel Network. His personal brand as a prolific angel investor in India generates significant inbound founder interest.

It is a single family office deploying the personal capital of Aniruddha Malpani. The firm does not manage external LP capital and does not charge management fees. Its operational tempo — high-volume seed checks, rapid decision-making, personal involvement — resembles an angel syndicate more than a traditional family office.

Both. The firm's primary activity is direct early-stage equity investments. Dr. Malpani also acts as a limited partner in several Indian venture capital funds, which serves as both a diversification strategy and a deal-flow sourcing mechanism.

The firm targets pre-seed and seed rounds almost exclusively. Checks typically range from $100,000 to $500,000. Selective follow-on investments occur for portfolio companies that demonstrate strong unit economics, but later-stage growth equity is not a focus.

There is no public list of exclusions. However, given the principal's background, the portfolio shows a heavy tilt toward digital health, enterprise software, and fintech. Hard-tech, deep science, and capital-intensive infrastructure plays are absent from the known portfolio, consistent with the firm's early-stage, asset-light bias.